Epidemiology and Management of Hepatocellular Carcinoma

Gastroenterology, Год журнала: 2018, Номер 156(2), С. 477 - 491.e1

Опубликована: Окт. 24, 2018

Язык: Английский

---

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology, Год журнала: 2019, Номер 20(2), С. 282 - 296

Опубликована: Янв. 19, 2019

Язык: Английский

---

Hepatocellular carcinoma

The Lancet, Год журнала: 2022, Номер 400(10360), С. 1345 - 1362

Опубликована: Сен. 6, 2022

Язык: Английский

---

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2020, Номер 18(4), С. 223 - 238

Опубликована: Дек. 21, 2020

Язык: Английский

---

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

Journal of Hepatology, Год журнала: 2014, Номер 60(6), С. 1268 - 1289

Опубликована: Март 27, 2014

Cholangiocarcinoma (CCA) comprises a heterogeneous group of cancers with pathologic features biliary tract differentiation, and is presumed to arise from the intra- or extrahepatic tract. Two recent papers suggest these may also directly transdifferentiation hepatocytes [1,2]. Gallbladder cancer distinct cholangiocarcinoma in epidemiology, pathobiology, clinical presentation management, should be considered different form [3].

Язык: Английский

---

Hepatocellular carcinoma: clinical frontiers and perspectives

Gut, Год журнала: 2014, Номер 63(5), С. 844 - 855

Опубликована: Фев. 14, 2014

Hepatocellular carcinoma (HCC) is one of the leading causes cancer-related death and currently main event to in patients with cirrhosis. Evolving information suggests that metabolic syndrome non-alcoholic liver disease may be an important cause HCC addition viral hepatitis alcohol-induced disease. The molecular pathogenesis extremely complex heterogeneous. To date has not impacted on treatment decisions. Periodic surveillance imaging cirrhosis widely practiced, especially because diagnostic, radiographic criteria for early-stage have been defined (including nodules between 1 2 cm) effective available tumours detected at early stage. Worldwide approach resection versus transplantation varies depending upon local resources, expertise donor availability. are discussed, controversial areas highlighted evidence-based recommendations provided. Several approaches intermediate stage disease, including radiofrequency ablation, transarterial chemoembolisation radioembolisation; rationale these therapies buttressed by appropriate outcome-based studies. For advanced systemic therapy sorafenib remains option best supported current data. Thus, while several trials failed improve benefits established therapies, studies assessing sequential or combined application those already known beneficial needed. Also, new concepts provided regards selecting stratifying second-line studies, which help explain failure prior

Язык: Английский

---

Immunotherapies for hepatocellular carcinoma

Nature Reviews Clinical Oncology, Год журнала: 2021, Номер 19(3), С. 151 - 172

Опубликована: Ноя. 11, 2021

Язык: Английский

---

Global burden of primary liver cancer in 2020 and predictions to 2040

Journal of Hepatology, Год журнала: 2022, Номер 77(6), С. 1598 - 1606

Опубликована: Окт. 5, 2022

Язык: Английский

---

Genetic Landscape and Biomarkers of Hepatocellular Carcinoma

Gastroenterology, Год журнала: 2015, Номер 149(5), С. 1226 - 1239.e4

Опубликована: Июнь 20, 2015

Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer-related death. Its mortality increased in Western populations, with minority patients diagnosed at early stages, when curative treatments are feasible. Only the multikinase inhibitor sorafenib is available for management advanced cases. During last 10 years, there been clear delineation landscape genetic alterations HCC, including high-level DNA amplifications chromosome 6p21 (VEGFA) and 11q13 (FGF19/CNND1), well homozygous deletions 9 (CDKN2A). The most frequent mutations affect TERT promoter (60%), associated an telomerase expression. can also be affected by copy number variations hepatitis B insertions, it found mutated preneoplastic lesions. TP53 CTNNB1 next prevalent mutations, affecting 25%-30% HCC patients, that, addition to low-frequency genes (eg, AXIN1, ARID2, ARID1A, TSC1/TSC2, RPS6KA3, KEAP1, MLL2), help define some core deregulated pathways HCC. Conceptually, these changes behave prototypic oncogenic addiction loops, being ideal biomarkers specific therapeutic approaches. Data from genomic profiling enabled proposal 2 molecular clusters (proliferation nonproliferation), differential enrichment prognostic signatures, pathway activation tumor phenotype. Translation discoveries into decisions unmet medical need this field.

Язык: Английский

---

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

Journal of Hepatology, Год журнала: 2017, Номер 67(1), С. 145 - 172

Опубликована: Апрель 18, 2017

Язык: Английский

---